Adam Hernandez

Adam Hernandez supports the National Cancer Institute’s procurement mission by managing complex acquisitions for advanced diagnostic and research technologies essential to cancer science. He oversees contracts for high-precision analytical instruments, laboratory services, and scientific consulting that enable cutting-edge genomic analysis and translational research. His work ensures the NCI’s research infrastructure remains at the forefront of precision medicine by securing mission-critical capabilities from industry partners with proven technical expertise in clinical diagnostics and laboratory automation. Hernandez maintains a primary working relationship with Roche Diagnostics Corporation, a leading provider of in vitro diagnostics and molecular testing platforms, reflecting a consistent preference for established vendors with validated capabilities in oncology-specific instrumentation. His contracting patterns indicate a reliance on large, technically sophisticated contractors capable of delivering integrated solutions for high-throughput sequencing, biomarker detection, and automated sample processing systems. While he engages primarily with industry leaders, his portfolio includes opportunities for small businesses, particularly in specialized testing and technical services. His procurement strategy prioritizes open competition, with 77.7% of awards issued without set-aside restrictions, yet he actively supports small business participation through Total Small Business Set-Asides (20.4%) and occasional 8(a) competed awards (1.9%). This balanced approach ensures both innovation scalability and socioeconomic compliance, aligning with federal goals while maintaining technical rigor in high-stakes research environments. Hernandez’s focus centers on NAICS 334516 (Analytical Laboratory Instrument Manufacturing), reflecting deep expertise in procuring next-generation sequencing systems, mass spectrometers, and automated liquid handling platforms. He also frequently sources services under NAICS 541380 (Testing Laboratories) and 541690 (Scientific Consulting), underscoring his role in acquiring end-to-end research support—from instrument deployment to data analysis and method validation—enabling the NCI’s mission to accelerate cancer breakthroughs through advanced laboratory science.